RVMD, RVMDW · CIK 0001628171 · operating
Revolution Medicines is a clinical-stage biotechnology company focused on developing targeted therapies for RAS-driven cancers. The company's pipeline centers on RAS(ON) inhibitors designed to bind specific RAS variants, either as monotherapy or in combination with companion inhibitors and other agents. Key programs include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) for solid tumors, and zoldonrasib G12D (RMC-9805), which is in phase 3 trials evaluating a combination approach in first-line pancreatic ductal adenocarcinoma patients. Additional development candidates target G12V, Q61H, and G13C RAS variants. The company also maintains a commercialization agreement with Aventis to research and develop SHP2 inhibitors for various indications.
As a clinical-stage company, Revolution Medicines does not generate significant product revenues. The company operates with approximately 883 full-time employees and is headquartered in Redwood City, California. Incorporated in Delaware in 2014, the company is publicly traded on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-5.95 | $-5.95 | -66.2% | |
| 2024 | $-3.58 | $-3.58 | +7.3% | |
| 2023 | $-3.86 | $-3.86 | -25.3% | |
| 2022 | $-3.08 | $-3.08 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-25 | 0001193125-26-071563 | SEC ↗ |
| 2024-12-31 | 2025-02-26 | 0000950170-25-027736 | SEC ↗ |
| 2023-12-31 | 2024-02-26 | 0000950170-24-020145 | SEC ↗ |
| 2022-12-31 | 2023-02-27 | 0000950170-23-004645 | SEC ↗ |
| 2021-12-31 | 2022-02-28 | 0000950170-22-002297 | SEC ↗ |
| 2020-12-31 | 2021-03-02 | 0001564590-21-010276 | SEC ↗ |
| 2019-12-31 | 2020-03-30 | 0001564590-20-014169 | SEC ↗ |